Vedolizumab serum trough concentrations with and without thiopurines in ulcerative colitis: The prospective VIEWS pharmacokinetics study

Table 2 Associations between vedolizumab serum trough concentrations and variable treatment endpoints, median (interquartile range)

Median vedolizumab serum trough concentrations (µg/mL)	No clinical remission	Clinical remission	P value	No endoscopic improvement	Endoscopic improvement	P value	No histologic remission	Histologic remission	P value
Week 01	14.0 (6.4-22.2)	15.7 (11.5-20.1)	0.47	13.9 (10.4-22.2)	15.9 (11.5-20.1)	0.69	16.0 (11.1-21.7)	15.5 (11.2-19)	0.44
Week 48	9.2 (5.4-21.7)	16.3 (12.5-22.4)	0.04	12.3 (8.1-21.9)	17.7 (13.5-21.1)	0.09	15.4 (9.8-21.9)	17 (12.6-21.0)	0.78
2 years2	12.4 (7.0-15.0)	17.7 (12.6-22.5)	0.02

¹Vedolizumab serum trough concentrations at week 0 vs remission rates at week 48.

²Vedolizumab serum trough concentrations at week 48 vs clinical remission at 2 years.